Expertise in
9
conditions

Dr. Adam C. Elnaggar

Oncology
The West Clinic PLLC
7945 Wolf River Blvd, 
Germantown, TN 
Accepting New Patients
Offers Telehealth
Expertise in
9
conditions
The West Clinic PLLC
7945 Wolf River Blvd, 
Germantown, TN 

Overview

Adam Elnaggar is an Oncologist practicing medicine in Germantown, Tennessee.

Dr. Elnaggar is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Ovarian Cancer, Endometrial Cancer, Adult Soft Tissue Sarcoma, Familial Colorectal Cancer, and Hernia Surgery.

He is actively involved in clinical research, co-authoring 51 peer reviewed articles and participating in 4 clinical trials. Dr. Elnaggar is currently accepting new patients.

Specialties

Oncology

Licenses

Obstetrics & Gynecology in TN

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
HMO Partners
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

The West Clinic PLLC
7945 Wolf River Blvd, Germantown, TN 38138

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 04, 2026
Intervention Type: Drug, Biological
Study Drugs: GEN-1, Carboplatin, Paclitaxel
Study Phase: Phase 1/Phase 2
A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial, Epithelial Ovarian Cancer, or Carcinosarcoma
A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial, Epithelial Ovarian Cancer, or Carcinosarcoma
Enrollment Status: Completed
Publish Date: August 01, 2025
Intervention Type: Drug
Study Drugs: Paclitaxel, DKN-01
Study Phase: Phase 2
A Phase II Trial of Niraparib and Dostarlimab Combination Therapy in Patients With Somatic Homologous Recombination Deficient Advanced or Metastatic Cancer
A Phase II Trial of Niraparib and Dostarlimab Combination Therapy in Patients With Somatic Homologous Recombination Deficient Advanced or Metastatic Cancer
Enrollment Status: Unknown
Publish Date: December 21, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients With Platinum-Resistant Ovarian Cancer (MOONSTONE)
A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients With Platinum-Resistant Ovarian Cancer (MOONSTONE)
Enrollment Status: Terminated
Publish Date: September 10, 2022
Intervention Type: Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

51 Total Publications

Prognostic Implications of Personalized Circulating Tumor DNA Testing in Patients with Advanced Urothelial Carcinoma Treated with Enfortumab Vedotin ± Pembrolizumab.
Prognostic Implications of Personalized Circulating Tumor DNA Testing in Patients with Advanced Urothelial Carcinoma Treated with Enfortumab Vedotin ± Pembrolizumab.
Journal: European urology oncology
Published: March 20, 2026
Similar Doctors
Expertise in
17
conditions
Dr. Amar J. Gajjar
Hematology | Oncology
Expertise in
17
conditions
Dr. Amar J. Gajjar
Hematology | Oncology
Referral may be required

St. Jude Children's Research Hospital

262 Danny Thomas Pl, 
Memphis, TN 
 (14.3 miles away)
901-595-2615
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Amar Gajjar is a Hematologist and an Oncologist practicing medicine in Memphis, Tennessee. Dr. Gajjar is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Medulloblastoma, Posterior Fossa Tumor, Brain Tumor, Embryonal Tumor with Multilayered Rosettes, and Posterior Fossa Decompression. Dr. Gajjar is currently accepting new patients.

Expertise in
21
conditions
Expertise in
21
conditions
Referral may be required

The West Clinic PLLC

7945 Wolf River Blvd, 
Germantown, TN 
 (0.1 miles away)
901-683-0055
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lee Schwartzberg is an Oncologist practicing medicine in Germantown, Tennessee. Dr. Schwartzberg is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Agranulocytosis, Febrile Neutropenia, Paget Disease of the Breast, and Tissue Biopsy. Dr. Schwartzberg is currently accepting new patients.

Expertise in
13
conditions
Dr. Giles W. Robinson
Hematology | Oncology
Expertise in
13
conditions
Dr. Giles W. Robinson
Hematology | Oncology
Referral may be required

St. Jude Children's Research Hospital

262 Danny Thomas Pl, 
Memphis, TN 
 (14.3 miles away)
901-595-5175
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Giles Robinson is a Hematologist and an Oncologist practicing medicine in Memphis, Tennessee. Dr. Robinson is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, Posterior Fossa Tumor, and Rhabdoid Tumor. Dr. Robinson is currently accepting new patients.

Frequently Asked Questions about Dr. Adam C. Elnaggar

How do I make an appointment with Dr. Adam C. Elnaggar?

You can book an appointment with Dr. Adam C. Elnaggar by calling their office at 901-683-0055. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Adam C. Elnaggar a top-rated expert for Ovarian Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Adam C. Elnaggar is classified as an Distinguished expert for Ovarian Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Adam C. Elnaggar specialize in?

While Dr. Adam C. Elnaggar is a Oncology, they have specific expertise in Ovarian Cancer, Endometrial Cancer, and Adult Soft Tissue Sarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Adam C. Elnaggar participate in research or clinical trials?

Yes. Dr. Adam C. Elnaggar has published 51 articles and abstracts on conditions like Ovarian Cancer. You can view a list of Dr. Adam C. Elnaggar's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Adam C. Elnaggar accept my insurance?

Dr. Adam C. Elnaggar accepts most major insurance plans, including Blue Cross Blue Shield and Cigna. We recommend calling the office directly at 901-683-0055 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Elnaggar's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 17 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile